ReviewFrontiers in pharmacology2020
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.Mycopathologia · 2021Pooled it
- Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.International immunopharmacology · 2021Pooled it
- Advancing Drug Repurposing for Rheumatoid Arthritis: Integrating Protein-Protein Interaction, Molecular Docking, and Dynamics Simulations for Targeted Therapeutic Approaches.Current issues in molecular biology · 2025Article
- Adverse drug reactions associated with COVID-19 management.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Differential expression patterns of purinergic ectoenzymes and the antioxidative role of IL-6 in hospitalized COVID-19 patient recovery.Frontiers in immunology · 2023Article
- Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.Environmental science and pollution research international · 2023Review
- Drug repurposing for the treatment of COVID-19.Journal of pharmacological sciences · 2022Review
- Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle.European journal of internal medicine · 2022Article
- Review
- SARS-CoV-2 Psychiatric Sequelae: A Review of Neuroendocrine Mechanisms and Therapeutic Strategies.The international journal of neuropsychopharmacology · 2022Article
- Editorial: Women in Inflammation Pharmacology: 2021.Frontiers in pharmacology · 2022Article
- The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.Journal of multidisciplinary healthcare · 2022Review
- Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin.Frontiers in immunology · 2022Article
- Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.Nature reviews. Immunology · 2021Review
- Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.The Lancet. Rheumatology · 2021Article
- Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is a condition caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 result in acute respiratory distress syndrome and death. A detrimental, hyper-inflammatory immune response with excess release of cytokines is the main driver of disease development and of tissue damage in these patients. Thus, repurposing of biologic agents and other pharmacological inhibitors of cytokines used for the treatment of various inflammatory conditions emerged as a logical therapeutic strategy to quench inflammation and improve the clinical outcome of COVID-19 patients. Evaluated agents include the interleukin one receptor blocker anakinra, monoclonal antibodies inhibiting IL-6 tocilizumab and sarilumab, monoclonal antibodies inhibiting granulocyte-monocyte colony stimulating factor and tumor necrosis factor, and Janus kinase inhibitors. In this review, we discuss the efficacy and safety of these therapeutic options based on direct personal experience and on published evidence from observational studies and randomized clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.